Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cutaneous T-Cell Lymphoma-Pipeline Review, H1 2015

Cutaneous T-Cell Lymphoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cutaneous T-Cell Lymphoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cutaneous T-Cell Lymphoma-Pipeline Review, H1 2015', provides an overview of the Cutaneous T-Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cutaneous T-Cell Lymphoma Overview 9

Therapeutics Development 10

Pipeline Products for Cutaneous T-Cell Lymphoma-Overview 10

Pipeline Products for Cutaneous T-Cell Lymphoma-Comparative Analysis 11

Cutaneous T-Cell Lymphoma-Therapeutics under Development by Companies 12

Cutaneous T-Cell Lymphoma-Therapeutics under Investigation by Universities/Institutes 14

Cutaneous T-Cell Lymphoma-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Cutaneous T-Cell Lymphoma-Products under Development by Companies 18

Cutaneous T-Cell Lymphoma-Products under Investigation by Universities/Institutes 20

Cutaneous T-Cell Lymphoma-Companies Involved in Therapeutics Development 21

Affimed Therapeutics AG 21

Chipscreen Biosciences Ltd 22

Cornerstone Pharmaceuticals, Inc. 23

Cyclacel Pharmaceuticals, Inc. 24

Eisai Co., Ltd. 25

Galderma S.A. 26

Innate Pharma SA 27

Johnson & Johnson 28

Karyopharm Therapeutics, Inc. 29

Kyowa Hakko Kirin Co., Ltd. 30

MedImmune, LLC 31

Neumedicines Inc. 32

Novartis AG 33

OncoSec Medical Inc. 34

Onyx Pharmaceuticals, Inc. 35

Sanofi 36

Soligenix, Inc. 37

Taiwan Liposome Company, Ltd. 38

Takeda Pharmaceutical Company Limited 39

TetraLogic Pharmaceuticals 40

Cutaneous T-Cell Lymphoma-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

A-dmDT390-bisFv-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AFM-13-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

alemtuzumab-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

AMP-224-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Angeloxin-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

bexarotene-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

brentuximab vedotin-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

carfilzomib-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

CIGB-128-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

CPI-613-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

CS-055-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

DNA IL-12-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

everolimus-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

IPH-4102-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

mogamulizumab-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

NMIL-121-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

quisinostat-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

sapacitabine-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

selinexor-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

SGX-301-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

SHP-141-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

trifarotene-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

vinorelbine tartrate-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Cutaneous T-Cell Lymphoma-Recent Pipeline Updates 102

Cutaneous T-Cell Lymphoma-Dormant Projects 164

Cutaneous T-Cell Lymphoma-Discontinued Products 167

Cutaneous T-Cell Lymphoma-Product Development Milestones 168

Featured News & Press Releases 168

Jan 07, 2015: FDA Grants Soligenix Fast TrackDesignation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma 168

Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma 168

Nov 03, 2014: IPH 4102 Preclinical Data Published In Cancer Research 169

Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 169

Aug 27, 2014: Innate Pharma's IPH4102 Receives Orphan Drug Designation In European Union 170

Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries 170

Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence 171

Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 172

Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma 173

Oct 08, 2013: OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study 173

Appendix 174

Methodology 174

Coverage 174

Secondary Research 174

Primary Research 174

Expert Panel Validation 174

Contact Us 174

Disclaimer 175

List of Tables

Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2015 10

Number of Products under Development for Cutaneous T-Cell Lymphoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Development by Companies, H1 2015 (Contd..1) 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Cutaneous T-Cell Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 21

Cutaneous T-Cell Lymphoma-Pipeline by Chipscreen Biosciences Ltd, H1 2015 22

Cutaneous T-Cell Lymphoma-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 23

Cutaneous T-Cell Lymphoma-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 24

Cutaneous T-Cell Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 25

Cutaneous T-Cell Lymphoma-Pipeline by Galderma S.A., H1 2015 26

Cutaneous T-Cell Lymphoma-Pipeline by Innate Pharma SA, H1 2015 27

Cutaneous T-Cell Lymphoma-Pipeline by Johnson & Johnson, H1 2015 28

Cutaneous T-Cell Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 29

Cutaneous T-Cell Lymphoma-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 30

Cutaneous T-Cell Lymphoma-Pipeline by MedImmune, LLC, H1 2015 31

Cutaneous T-Cell Lymphoma-Pipeline by Neumedicines Inc., H1 2015 32

Cutaneous T-Cell Lymphoma-Pipeline by Novartis AG, H1 2015 33

Cutaneous T-Cell Lymphoma-Pipeline by OncoSec Medical Inc., H1 2015 34

Cutaneous T-Cell Lymphoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 35

Cutaneous T-Cell Lymphoma-Pipeline by Sanofi, H1 2015 36

Cutaneous T-Cell Lymphoma-Pipeline by Soligenix, Inc., H1 2015 37

Cutaneous T-Cell Lymphoma-Pipeline by Taiwan Liposome Company, Ltd., H1 2015 38

Cutaneous T-Cell Lymphoma-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 39

Cutaneous T-Cell Lymphoma-Pipeline by TetraLogic Pharmaceuticals, H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Stage and Target, H1 2015 43

Number of Products by Stage and Mechanism of Action, H1 2015 45

Number of Products by Stage and Route of Administration, H1 2015 47

Number of Products by Stage and Molecule Type, H1 2015 49

Cutaneous T-Cell Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 102

Cutaneous T-Cell Lymphoma-Dormant Projects, H1 2015 164

Cutaneous T-Cell Lymphoma-Dormant Projects (Contd..1), H1 2015 165

Cutaneous T-Cell Lymphoma-Dormant Projects (Contd..2), H1 2015 166

Cutaneous T-Cell Lymphoma-Discontinued Products, H1 2015 167

List of Tables

Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2015 10

Number of Products under Development for Cutaneous T-Cell Lymphoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Development by Companies, H1 2015 (Contd..1) 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Cutaneous T-Cell Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 21

Cutaneous T-Cell Lymphoma-Pipeline by Chipscreen Biosciences Ltd, H1 2015 22

Cutaneous T-Cell Lymphoma-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 23

Cutaneous T-Cell Lymphoma-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 24

Cutaneous T-Cell Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 25

Cutaneous T-Cell Lymphoma-Pipeline by Galderma S.A., H1 2015 26

Cutaneous T-Cell Lymphoma-Pipeline by Innate Pharma SA, H1 2015 27

Cutaneous T-Cell Lymphoma-Pipeline by Johnson & Johnson, H1 2015 28

Cutaneous T-Cell Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 29

Cutaneous T-Cell Lymphoma-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 30

Cutaneous T-Cell Lymphoma-Pipeline by MedImmune, LLC, H1 2015 31

Cutaneous T-Cell Lymphoma-Pipeline by Neumedicines Inc., H1 2015 32

Cutaneous T-Cell Lymphoma-Pipeline by Novartis AG, H1 2015 33

Cutaneous T-Cell Lymphoma-Pipeline by OncoSec Medical Inc., H1 2015 34

Cutaneous T-Cell Lymphoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 35

Cutaneous T-Cell Lymphoma-Pipeline by Sanofi, H1 2015 36

Cutaneous T-Cell Lymphoma-Pipeline by Soligenix, Inc., H1 2015 37

Cutaneous T-Cell Lymphoma-Pipeline by Taiwan Liposome Company, Ltd., H1 2015 38

Cutaneous T-Cell Lymphoma-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 39

Cutaneous T-Cell Lymphoma-Pipeline by TetraLogic Pharmaceuticals, H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Stage and Target, H1 2015 43

Number of Products by Stage and Mechanism of Action, H1 2015 45

Number of Products by Stage and Route of Administration, H1 2015 47

Number of Products by Stage and Molecule Type, H1 2015 49

Cutaneous T-Cell Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 102

Cutaneous T-Cell Lymphoma-Dormant Projects, H1 2015 164

Cutaneous T-Cell Lymphoma-Dormant Projects (Contd..1), H1 2015 165

Cutaneous T-Cell Lymphoma-Dormant Projects (Contd..2), H1 2015 166

Cutaneous T-Cell Lymphoma-Discontinued Products, H1 2015 167

List of Figures

Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2015 10

Number of Products under Development for Cutaneous T-Cell Lymphoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Top 10 Targets, H1 2015 42

Number of Products by Stage and Top 10 Targets, H1 2015 42

Number of Products by Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Top 10 Routes of Administration, H1 2015 46

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 47

Number of Products by Top 10 Molecule Types, H1 2015 48

Number of Products by Stage and Top 10 Molecule Types, H1 2015 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Affimed Therapeutics AG

Chipscreen Biosciences Ltd

Cornerstone Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

Eisai Co., Ltd.

Galderma S.A.

Innate Pharma SA

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

MedImmune, LLC

Neumedicines Inc.

Novartis AG

OncoSec Medical Inc.

Onyx Pharmaceuticals, Inc.

Sanofi

Soligenix, Inc.

Taiwan Liposome Company, Ltd.

Takeda Pharmaceutical Company Limited

TetraLogic Pharmaceuticals

Cutaneous T-Cell Lymphoma Therapeutic Products under Development, Key Players in Cutaneous T-Cell Lymphoma Therapeutics, Cutaneous T-Cell Lymphoma Pipeline Overview, Cutaneous T-Cell Lymphoma Pipeline, Cutaneous T-Cell Lymphoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com